MA43331A - Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7 - Google Patents

Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7

Info

Publication number
MA43331A
MA43331A MA043331A MA43331A MA43331A MA 43331 A MA43331 A MA 43331A MA 043331 A MA043331 A MA 043331A MA 43331 A MA43331 A MA 43331A MA 43331 A MA43331 A MA 43331A
Authority
MA
Morocco
Prior art keywords
smad7
treatment
methods
oligonucleotide
senses
Prior art date
Application number
MA043331A
Other languages
English (en)
Inventor
Giovanni Monteleone
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MA43331A publication Critical patent/MA43331A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le traitement d'une maladie intestinale inflammatoire (par exemple, la maladie de crohn et la colite ulcéreuse) en utilisant des nucléotides antisens dirigés contre des formes polymorphes (par exemple, celles contenant des polymorphismes de nucléotides simples) de l'arnm smad7. L'invention concerne donc des procédés de traitement pour des sujets présentant des formes polymorphes de smad7 et d'oligonucléotides antisens qui ciblent spécifiquement des transcrits d'arnm smad7 contenant des polymorphismes.
MA043331A 2014-10-17 2015-10-16 Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7 MA43331A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462065598P 2014-10-17 2014-10-17

Publications (1)

Publication Number Publication Date
MA43331A true MA43331A (fr) 2017-08-23

Family

ID=54330761

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043331A MA43331A (fr) 2014-10-17 2015-10-16 Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7

Country Status (12)

Country Link
US (2) US10337004B2 (fr)
EP (1) EP3207136A1 (fr)
JP (1) JP2017532961A (fr)
KR (1) KR20170069262A (fr)
CN (1) CN107406851A (fr)
AU (1) AU2015332624A1 (fr)
CA (1) CA2964667A1 (fr)
EA (1) EA201790867A1 (fr)
IL (1) IL251717A0 (fr)
MA (1) MA43331A (fr)
MX (1) MX2017004973A (fr)
WO (1) WO2016059239A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
PT3121280T (pt) 2008-11-13 2025-07-01 Nogra Pharma Ltd Composições antissentido e método de fabrico e utilização das mesmas
MX350087B (es) 2011-09-15 2017-08-24 Nogra Pharma Ltd Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7.
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
EP3213070A2 (fr) * 2014-10-17 2017-09-06 Nogra Pharma Limited Procédés de dosage et de suivi d'un traitement avec un oligonucléotide antisens de smad7 utilisant des teneurs en marqueurs biologiques
MA43331A (fr) 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
US11162097B2 (en) * 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
CA3048334A1 (fr) * 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions d'oligonucleotide antisens de proteine smad7 et methodes de traitement ou de prevention du psoriasis
AU2021260967A1 (en) * 2020-04-24 2022-10-20 Nogra Pharma Limited Compositions of SMAD7 antisense oligonucleotides (ASO) and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2388968T3 (es) 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
PT3121280T (pt) 2008-11-13 2025-07-01 Nogra Pharma Ltd Composições antissentido e método de fabrico e utilização das mesmas
EP2389390B1 (fr) * 2009-01-26 2020-11-04 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Moyens et procédés de modulation de l'expression de la protéine notch3 et/ou de la région codante de notch3 ; compositions et utilisation de ceux-ci dans le traitement de cadasil
EP3208347B1 (fr) * 2010-02-08 2019-08-14 Ionis Pharmaceuticals, Inc. Réduction sélective de variantes alléliques
MX350087B (es) * 2011-09-15 2017-08-24 Nogra Pharma Ltd Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7.
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
MX363746B (es) 2013-03-15 2019-04-01 Nogra Pharma Ltd Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal.
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
EP3213070A2 (fr) 2014-10-17 2017-09-06 Nogra Pharma Limited Procédés de dosage et de suivi d'un traitement avec un oligonucléotide antisens de smad7 utilisant des teneurs en marqueurs biologiques
WO2015011694A2 (fr) 2014-10-17 2015-01-29 Celgene Corporation Isotopologues d'oligonucléotides antisens smad7
MA43331A (fr) 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
MA41271A (fr) 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
JP2018531936A (ja) 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法
JP2018529726A (ja) 2015-09-30 2018-10-11 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｔｌｒ調節因子及び使用方法

Also Published As

Publication number Publication date
CA2964667A1 (fr) 2016-04-21
IL251717A0 (en) 2017-06-29
WO2016059239A1 (fr) 2016-04-21
US20190338283A1 (en) 2019-11-07
JP2017532961A (ja) 2017-11-09
US20170240893A1 (en) 2017-08-24
MX2017004973A (es) 2017-12-07
AU2015332624A1 (en) 2017-05-04
EA201790867A1 (ru) 2017-08-31
CN107406851A (zh) 2017-11-28
US10337004B2 (en) 2019-07-02
KR20170069262A (ko) 2017-06-20
EP3207136A1 (fr) 2017-08-23

Similar Documents

Publication Publication Date Title
MA43331A (fr) Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
CY1121037T1 (el) Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
ZA201807286B (en) Angiotensinogen (agt) irna compositions and methods of use thereof
PH12017500669A1 (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
MX2017008183A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
EA201692537A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
EA201690526A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
MX2017011013A (es) Terapia de oligonucleotidos para amaurosis congenita de leber.
MD4760B1 (ro) Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
DK3265102T3 (da) Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituerede-2-modificerede-n6-substituerede purinnukleotider til hcv-behandling
CU24574B1 (es) Oligonucleótido que contiene una secuencia nucleobase para disminuir la expresión de tau
WO2017055611A3 (fr) Méthodes d'utilisation d'oligonucléotides antisens smad7 sur la base de l'expression de biomarqueurs
EP3353332A4 (fr) Enlèvement sélectif de métaux nobles en utilisant des fluides, y compris des fluides contenant des ions de nitrate
EA201890379A1 (ru) Терапевтические олигонуклеотиды
NZ738100A (en) Igfbp3 and uses thereof
EA201791471A1 (ru) Способы применения антисмысловых олигонуклеотидов smad7
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease
ES2671745T3 (es) Detección de Neisseria gonorrhoeae
MX2018006445A (es) Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos.
AR105291A1 (es) Métodos y conjuntos de elementos para la detección del oídio
WO2016145362A3 (fr) Inhibiteurs de protéine dek et procédés associés
MA44836A (fr) Procédés de traitement du syndrome polykystique des reins
CL2016000299A1 (es) Metodo para la deteccion de resistencia a piretroides en crustaceos usando secuencias oligonucleotidas utiles en la deteccion de resistencia a piretroide.